PRIME THERAPEUTICS for PRIME THERAPEUTICS
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
H.R. 965/S. 340: The Creating and Restoring Equal Access to Equivalent Samples (CREATES Act). Implementation of the e-prescribing provisions of the controlled substances provisions of the SUPPORT Act (P.L. 115-271). S. 1895: The Lower Health Care Costs Act, Sec. 306 Health Plan Oversight of PBMs. S. 2119: The Insulin Price Reduction Act, requires private health insurance plans and Medicare Part D plans to eliminate rebates for insulin and limit out of pocket costs. H.R. 3: Elijah E. Cummings Lower Drugs Costs Now Act, provisions to modernize the Part D benefit and provisions that require HHS to negotiate prices for certain drugs. H.R. 19/S. 3129: The Lower Costs, More Cures Act, reforms drug pricing by promoting greater competition and redesigns the Medicare Part D drug benefit. H.R. 5304: legislation to amend title XXVII of the Public Health Service Act to require health plan oversight of pharmacy benefit manager services.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JULIE CAROL CANTOR-WEINBERG | — |
Medicare/Medicaid MMM
H.R. 965/S. 340: The Creating and Restoring Equal Access to Equivalent Samples (CREATES Act). Implementation of the e-prescribing provisions of the controlled substances provisions of the SUPPORT Act (P.L. 115-271). S. 1895: The Lower Health Care Costs Act, Sec. 306 Health Plan Oversight of PBMs. S. 2199: The Insulin Price Reduction Act, requires private health insurance plans and Medicare Part D plans to eliminate rebates for insulin and limit out of pocket costs. H.R. 3: Elijah E. Cummings Lower Drugs Costs Now Act, provisions to modernize the Part D benefit and provisions that require HHS to negotiate prices for certain drugs. H.R. 19/S. 3129: The Lower Costs, More Cures Act, reforms drug pricing by promoting greater competition and redesigns the Medicare Part D drug benefit. S. 3013: Encouraging Innovative Benefit Design to Lower Costs for Seniors Act, provisions allowing for the offering of additional prescription drug plans under Medicare Part D. S. 2543: The Prescription Drug Pricing Reduction Act, legislation to amend Medicare and Medicaid to lower prescription drug prices and strengthen safeguards related to prescription drug. Provisions related to inflation protection and PBM transparency. Medicare Advantage and Part D Drug Pricing Final Rule, (CMS-4180-F), provisions related to pharmacy Direct and Indirect Negotiation and a real-time benefit tool. Outreach and education on pharmacy DIR in Medicare Part D. H.R. 2115: Public Disclosure of Drug Discounts and Real-time Beneficiary Drugs Costs Act, provisions requiring HHS to publish information online about discounts under Medicare Advantage and Part D and requirements related to real-time benefits tool implementation. H.R. 1791: The Payment Commission Data Act of 2019, legislation that would require government commission to receive rebate and other data from PBMs/Part D plans.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JULIE CAROL CANTOR-WEINBERG | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.